Réf :HematoStat.net ; 2 (3) : V47   Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients DOI: 10.1182/blood.2021013445

Réf :HematoStat.net ; 2 (3) : V46   Circulating Tumor DNA in Lymphoma: Principles and Future Directions doi: 10.1158/2643-3230.BCD-21-0029

Réf :HematoStat.net ; 2 (3) : V45   Polatuzumab Vedotin in Précédently Untreated Diffuse Large B-Cell Lymphoma DOI: 10.1056/NEJMoa2115304

Réf :HematoStat.net ; 2 (3) : V44   Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.  https://doi.org/10.1016/ S1470-2045(21)00139-X

Réf :HematoStat.net ; 2 (3) : V43   The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cellymphoma https://doi.org/10.1016/j.annonc.2021.12.002  

Réf :HematoStat.net ; 2 (3) : V42   Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. […]

Réf :HematoStat.net ; 2 (1) : V41   Tanya T Mararand al.Thrombin spatial distribution determines Protein C activation during hemostasis and thrombosis. Blood. 2021 Dec 10;blood.2021014338. doi: 10.1182/blood.2021014338 PMID: 34890454

Réf :HematoStat.net ; 2 (1) : V40 Marco Zuin and al.Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis. Thromb Res. 2022 Jan;209:94-98.doi: […]

Réf :HematoStat.net ; 2 (1) : V39   Anna Collins and al.The risk of venous thromboembolism in early pregnancy loss: Review of the literature and current guidelines and the need […]

Réf :HematoStat.net ; 2 (1) : V38 Matteo Nicola Dario Di Minnoand al. Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of […]